Combination Therapy of Multiple Micro Trauma Technology on Hepatocellular Carcinoma

Abstract

Objective: To compare efficacy of therapy scheme as Transhepatic Artery Chemoembolization (TACE) + Radiofre quency Ablation (RFA) + Introportal Vein Chemotherapy (PVC) + Percutaneous Ethanol Injection (PEI) therapy (quadruplet group) with TACE + RFA combinational therapy (diad group) in treating hepatocellular carcinoma (HCC). Methods: 25 cases in quadruplet group were treated by TACE for 3 weeks, then by RFA, after 2 months, by PVC + PEI; 23 cases in diad group were treated by TACE for 3 weeks and then by PEI. After completion of each treatment course in both groups, Alphafetoprotein (AFP) was tested 2 months later ; abdomen colorful doppler, CT and AFP were re tested 6 months later. Results: AFP was significantly decreased in 23 cases of quadruplet group and 20 cases of diad group among those with AFP positive results. 6 months later, examinations of CT, colorful Doppler and AFP in two groups showed: quadruplet group has significantly decreased ( X 2 = 6.81, P < 0.01) blood supply of cancer tissue and significantly diminished ( X 2 = 8.29, P < 0.01) tumor size, few cases with AFP elevation ( X 2 = 5.06, P < 0.05); lower 1 year relapse rate and two years mortality than that in diad group ( X 2 = 5.30, P < 0.05). Conclusion: TACE + RFA + PVC + PEI combinational therapy is a safe double intervention treatment for HCC scheme with less side effects, which is better than TACE + PEI scheme in killing remnant tumor and reducing relapse.